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Abstract
Background: Medulloblastoma (MB) is the most common pediatric brain tumor. Current treatment regimes
consisting of primary surgery followed by radio- and chemotherapy, achieve 5-year overall survival rates of only
about 60 %. Therapy-induced endocrine and neurocognitive deficits are common late adverse effects. Thus,
improved antitumor strategies are urgently needed. In this study, we combined irradiation (IR) together with
epigenetic modifiers and differentiation inducers in a multimodal approach to enhance the efficiency of tumor
therapy in MB and also assessed possible late adverse effects on neurogenesis.
Methods: In three human MB cell lines (DAOY, MEB-Med8a, D283-Med) short-time survival (trypan blue exclusion
assay), apoptosis, autophagy, cell cycle distribution, formation of gH2AX foci, and long-term reproductive survival
(clonogenic assay) were analyzed after treatment with 5-aza-2′-deoxycytidine (5-azadC), valproic acid (VPA),
suberanilohydroxamic acid (SAHA), abacavir (ABC), all-trans retinoic acid (ATRA) and resveratrol (RES) alone or
combined with 5-aza-dC and/or IR. Effects of combinatorial treatments on neurogenesis were evaluated in cultured
murine hippocampal slices from transgenic nestin-CFPnuc C57BL/J6 mice. Life imaging of nestin-positive neural
stem cells was conducted at distinct time points for up to 28 days after treatment start.
Results: All tested drugs showed a radiosynergistic action on overall clonogenic survival at least in two-outof-three
MB cell lines. This effect was pronounced in multimodal treatments combining IR, 5-aza-dC and a second drug.
Hereby, ABC and RES induced the strongest reduction of clongenic survival in all three MB cell lines and led to the
induction of apoptosis (RES, ABC) and/or autophagy (ABC). Additionally, 5-aza-dC, RES, and ABC increased the S
phase cell fraction and induced the formation of gH2AX foci at least in oneout-of-three cell lines. Thereby, the
multimodal treatment with 5-aza-dC, IR, and RES or ABC did not change the number of normal neural progenitor
cells in murine slice cultures.
Conclusion: In conclusion, the radiosensitizing capacities of epigenetic and differentiation-inducing drugs
presented here suggest that their adjuvant administration might improve MB therapy. Thereby, the combination of
5-aza-dC/IR with ABC and RES seemed to be the most promising to enhance tumor control without affecting the
normal neural precursor cells.
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Background
Medulloblastoma (MB) is the most common malignant
brain tumor (WHO °IV) in children aged < 15 years [1].
The MB standard therapy consists of primary tumor sur-
gery followed by radiation therapy and/or chemotherapy.
Current therapy regimes are mainly guided by tumor
histology, metastasic disease, extend of resection, and
patient age. New trials additionally include molecular
factors like ß-catenin protein and MYC/MYCN gene
amplification status. Patients with metastases receive a
more intensive treatment compared to metastases-free
patients. No radiation therapy but a more aggressive
chemotherapy is given to children below 4 years to avoid
radiation-related adverse late effects, like neuroendo-
crine and neurocognitive deficits. The 5-year overall
survival of approximately 60 % implies the urgent need
of improved antitumor therapies to enhance the outcome
especially of high-risk patients (infants, metastatic
disease: ~ 55 % of all MB patients).
During embryonal development, MB arises from
neural precursor cells in different zones of the rhombic
lip, wherefrom they are growing into the cerebellum or
the brain stem [2]. It is widely believed that tumor
formation is initiated by genetic, gene-regulatory, or
epigenetic abnormalities, which inhibit the normal
neuronal or glial differentiation [3]. In 70–90 % of
primary MBs, hypermethylation of gene promotors of
tumor suppressor genes (TSG) is observed, which
leads to their inactivation and, finally, to unrestricted
proliferation and blockage of apopotosis [3]. Hence,
the application of approved epigenetic modifiers, like
5-aza-2′-deoxycytidine (5-aza-dC, decitabine), valproic
acid (VPA), or suberanilohydroxamic acid (SAHA,
Vorinostat®), which have been shown by us [4] and
others [5–8] to demethylate TSG, seems to be a suit-
able approach to inhibit tumor cell growth. These sub-
stances induce a cell cycle arrest at G2/M [9–11],
where cells are most radiosensitive (reviewed in [12]).
Therefore, synergistic effects with IR might be antici-
pated. Besides, MBs are mostly poorly differentiated
tumors [13, 14] containing 6–21 % potential tumor
stem cells (TSC) [15], which are often chemo- and
radiotherapy-resistant (reviewed in [16]) and held
responsible for tumor relapse (reviewed in [17]).
Differentiation-inducing drugs like all-trans retinoic
acid (ATRA), abacavir (ABC), or resveratrol (RES) are
applied in this study for their potential to induce the
maturation of MB tumor stem cells and, thereby, to
suppress their cancer-forming capacities (previously
described in [18]). Besides, ATRA is able to inhibit
MB cell growth by suppression of the OTX2 (ortho-
denticle homeobox 2) gene, which is overexpressed in
the majority of medulloblastomas [19]. In addition,
tumor cell-specific activity might be exerted by ABC
through telomerase inhibition, which is enhanced in
70 % of MBs [20] and by RES through its Cu(II)-
dependent oxidative effects, which may induce cell
death especially in low pH environments. As tumor
cells are often acidic due to their glycolysis depend-
ence and have elevated copper levels, they might be
more sensitive to RES than normal cells [21].
Recently, we tested single and combinatorial effects of
the de novo methyltransferase (DNMT) inhibitor 5-aza-
dC with IR [4] or with other epigenetic/differentiation-
inducing drugs on the metabolic activity and reproduc-
tive survival of human MB cells [18]. Here, we combined
for the first time IR, an integral part of MB standard
therapy in children > 4 years, with 5-aza-dC and pre-
viously evaluated [18] drugs (VPA, SAHA, RES, ABC,
ATRA) in a multimodal approach to further enhance the
efficiency of MB tumor therapy. As brain tumor treat-
ment is known to induce cognitive deficits by inhibition
of hippocampal neurogenesis [22], also potential ad-
verse effects have been evaluated using a murine
entorhino-hippocampal slice culture model.
Methods
All methods were performed at room temperature unless
otherwise noted.
Modulators
5-Aza-dC (trade name Dacogen®), ATRA, RES, and
VPA were purchased from Sigma-Aldrich (Munich,
Germany). ABC hemisulfate was kindly provided from
GlaxoSmithKline (Hamburg, Germany) and SAHA (trade
name Zolinza®) from MSD (Haar, Germany). Stock solu-
tions were prepared as follows and stored at - 20 °C:
10 mM 5-aza-dC in PBS; 500 μM ATRA in 10 % ethanol
(stored at - 80 °C); 500 μM RES in 1 % ethanol; 1 M VPA
in PBS; 100 mM ABC in PBS; 100 μM SAHA in 0.25 %
DMSO. Further working solutions were made in PBS
and equal volumes were administered into the culture
medium. To exclude effects based on ethanol or DMSO
applications, appropriate controls were implemented.
Drug concentrations of 5-aza-dC, SAHA, ATRA, and
RES applied here are guided by achievable serum levels
[23–26]. However, concentrations of VPA and ABC are
2- to 25-fold higher than tested in pharmacokinetic
studies until now [27, 28].
Cell lines
The human MB cell line MEB-Med8a was kindly pro-
vided by Prof. T. Pietsch (Department of Neuropathology,
University of Bonn Medical Centre, Bonn, Germany). The
MB cell lines D283-Med and DAOY were purchased
from ATCC cell biology collection (Manassas VA, USA).
DAOY cells are TP53-mutated, whereas MEB-Med8a
and D283-Med cell lines are wild-type TP53 [29, 30].
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D283-Med and DAOY were maintained in MEM (Sigma-
Aldrich, Munich, Germany) including 2 mM L-glutamine
(Biochrom, Berlin, Germany), MEB-Med8a in DMEM
with 4.5 g glucose (Lonza, Basel, Switzerland), all supple-
mented with 10 % fetal calf serum (PAA, Yeovil, Somerset,
UK), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Biochrom, Berlin, Germany) at 37 °C and 5 % CO2 unless
otherwise noted.
Animals
Mouse breeding was performed in the animal facility of
the Faculty of Medicine, University of Leipzig according
to European (Council Directive 86/609/EEC) and German
(Tierschutzgesetz) guidelines for the welfare of experi-
mental animals. Nestin-CFPnuc C57BL/J6 mice, generated
by Encinas et al. [31] were housed in a 12 h/12 h light/
dark cycle with access to food and water ad libitum.
Preparation of murine entorhino-hippocampal slice
cultures
Organotypic entorhino-hippocampal slice cultures were
generated from nestin-CFPnuc C57BL/J6 mice, postnatal
day (p) 3 to 6 as initially described by Gahwiler et al.
[32] and modified by Kluge et al. [33]. Briefly, after
decapitation of the mice, brains were removed and
350 μm-thick horizontal slices were prepared on a vib-
ratome (Leica VT 1000). The entorhino-hippocampal
structure was then resected and transferred onto mem-
brane inserts (Millicell PICMORG50, Millipore) in six-
well cell culture plates. Tissue slices were cultivated at
37 °C and 5 % CO2 and cell culture medium (MEM,
Invitrogen; 25 % HBSS, Invitrogen; 25 % horse serum,
Invitrogen; 1 % L-glutamine, Sigma; 1 % penicillin/strepto-
mycin, Lonza; 1 % glucose, Applichem) was renewed three
times a week. Slices were cultivated for 7-14 days before
start of the experiment to allow tissue healing.
Single drug and multimodal treatment of cell lines
To examine concentration effects of the single drugs,
cells were seeded in cell culture flasks and five different
concentrations of the modulator were added after 24 h
and again at medium renewal 4 days after seeding. For
combination experiments, cells were seeded and, 24 h
later, treated simultaneously with IC 90 of 5-aza-dC and
a second drug (concentrations see Table 1). After three
treatment days, cells were irradiated with 2 or 8 Gy,
medium was renewed, and 5-aza-dC and the second
drug were supplemented. After overall six treatment
days, cells were seeded for clonogenic assay.
Single drug and multimodal treatment of tissue slices
To assess the neurotoxic potential of the most promising
multimodal settings, murine enthorino-hippocampal tis-
sue slices were treated (day 0) with 0.5 μM 5-aza-dC,
40 μM RES or 250 μM ABC, corresponding to the
maximal IC 90 in the three cell lines. After 72 h, single
dose irradiation with 8 Gy was performed, medium was
renewed, and the drugs were supplemented for additional
72 h as done for the clonogenic assay. Ethanol control
contains 0.023 % ethanol which corresponds to the etha-
nol concentration in the resveratrol treated samples.
Irradiation
Cell/slice cultures were irradiated with a single dose
using a 150 kV X-ray machine (DARPAC 150-MC) at a
dose rate of 0.86 Gy/min.
Relative number of vital cells
To determine the number of vital cells, cells were
counted using the trypan blue exclusion assay. The rela-
tive number of vital cells is calculated from vital cell
counts after treatment normalized to the initially seeded
vital cell number.
Cell cycle distribution
To examine changes on cell cycle distribution 24 h and
72 h after treatment, cells were harvested, washed twice
with PBS, and fixed with 70 % ethanol at 4 °C overnight.
Afterwards, cells were washed twice in PBS, incubated
with RNAseA solution (0.1 mg/ml) 20 min at 37 °C,
and stained with propidium iodide (50 μg/ml) 5 min at
4 °C. The DNA staining by propidium iodide and the
cell cycle distribution were then assessed by flow cy-
tometry (Beckman coulter, EPICS XL) using EXPO32
software.
DNA double-strand break detection
To detect DNA double-strand breaks, nuclear staining
of gH2AX repair protein was executed after 1 h/24 h
treatment or 1 h/24 h after IR. Cells were seeded on
chamber slides (DAOY, MEB-Med8a; adherent cells) or
in 6-well cell culture plates (D283-Med, suspension
cells) and irradiated (8 Gy) or treated with IC 90 of 5-
Table 1 Drug concentrations for the combinatorial treatment of
human MB cells
cell line D283-Med MEB-Med8a DAOY
5-aza-dC 0.05 μM 0.1 μM 0.5 μM
VPA 3 mM 1 mM 2 mM
SAHA 1 μM 2 μM 2 μM
Abacavir 0.25 mM 0.04 mM 0.24 mM
ATRA 1.5 μM 10 μM 10 μM
Resveratrol 11 μM 9.5 μM 40 μM
For combination experiments, IC 90 values were calculated from single drug
clonogenic assays for each cell line separately and indicate the drug
concentration leading to 90 % inhibition of colony formation. For SAHA and
ATRA, the maximal tolerated plasma concentrations were used in MEB-Med8a
and DAOY, leading to IC 71/IC 82 (SAHA) or IC 46/IC 72 (ATRA), respectively
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aza-dC, RES, or ABC (concentrations see Table 1) 24 h
later. For staining, D283-Med cells were harvested by
scratching and transferred to 96-well U bottom plates.
Cells were fixed with 2 % formaldehyde in PBS for
15 min washed three times with PBS and permeabilized
with 0.2 % Triton-X in PBS containing 1 % bovine serum
albumine (PBS-BSA) for 5 min on ice. Then, cells were
washed once with PBS-BSA, blocked with 3 % BSA in
PBS for 1 h, and incubated with 10 μg/ml mouse anti-
phospho histone H2A.X (Ser 139) antibody (clone
JBW301; Millipore) or corresponding mouse IgG 1
isotype control (Acris), diluted in PBS-BSA containing
0.5 % Tween 20 (PBS-BSA-Tween), for 1 h. After three
washes with PBS-BSA-Tween, cells were incubated
with 2 μg/ml secondary antibody (goat anti-mouse
Alexa 568 IgG F(ab’)2; Invitrogen), diluted in PBS-
BSA-Tween for 1 h in the dark. Then, cells were
washed three times with PBS-BSA-Tween, counter-
stained with DAPI (0.5 μg/ml) 5 min, cytospins prepared
for D283-Med cells and mounted (fluorescence mounting
medium, DAKO).
DNA double-strand breaks (DSB) were analyzed in 50
cells for each treatment. A maximum of 30 gH2AX-foci
per nucleus were counted by fluorescence microscopy.
Apoptosis
Apoptotic cells were determined using the FAM-FLICA™
in vitro Caspase 3/7 Detection Kit (Immunochemistry
Technologies) according to the manufacturers’ instruc-
tions. In brief, 18 h after IR with 2 Gy or treatment with
IC 90 of 5-aza-dC, RES, or ABC (concentrations see
Table 1), cells were harvested and stained with FLICA™
solution for 60 min at 37 °C. After washing three times,
cells were counterstained with propidium iodide (2 μg/
ml) and analyzed by flow cytometry (Beckman coulter,
EPICS XL).
In addition, the PI staining of sub-G1 cells (see cell
cycle distribution in method section) was quantified as a
second detection method for apoptotic cells.
Autophagy
Autophagy was analyzed with the Cyto-ID® Autophagy
Detection Kit (ENZO), according to the manufac-
turers’ instructions. The CytoID® detection reagent, a
cationic amphiphilic tracer (CAT) selectively labels
pre-autophagosomes, autophagosomes and auto(phago)-
lysosomes with negligible staining of lysosomes. Rapa-
mycin and chloroquine were applied as positive and
negative controls. Cells were harvested 18 h after ir-
radiation (2 Gy) or treatment with IC 90 of 5-aza-dC,
RES, or ABC (concentrations see Table 1) and stained
with Cyto-ID® solution for 30 min at 37 °C before flow
cytometric analysis.
The autophagy activity factor (AAF) was calculated as
follows:
AAF ¼ 100 MFI treated ‐ MFI control
MFI control
AAF autophagy activity factor
MFI mean fluorescence intensity
Clonogenic survival
Subsequently to cell treatment, vital cells were counted
using trypan blue exclusion test and seeded at two dif-
ferent cell densities in triplicates in 6 well cell culture
plates. Normal medium without modulators was added.
Ten to 14 days later, colonies were washed with PBS,
fixed with ice-cold ethanol/acetone (1:2) for 10 min,
stained with Giemsa solution (1:2 with distilled water)
for 5 min, and washed with distilled water. Colonies
with > 50 cells were counted; the quotient of counted
colonies to seeded cells determined the plating efficiency
(PE). The ratio between PE of treated cells and PE of un-
treated cells represented the clonogenic surviving frac-
tion (SF) of seeded cells. The overall clonogenic survival
was calculated from the relative number of vital cells
multiplied with the SF.
‘Life imaging’ analysis of neural progenitor cells
Nestin-positive neural stem cells [34] were visualized
by their nuclear-expressed cyan fluorescent protein
(CFPnuc) using a confocal ‘life imaging’ microscope
(Olympus IX81). Slices were imaged at 20-fold magnifi-
cation at day 0 (before treatment), day 7, day 14, day 21
and 28 after treatment start. Z-stacks of three images at
4 μm intervals were prepared and fluorescent cells were
quantified by ImageJ (https://imagej.nih.gov/ij/).
Statistics
Statistical analysis of two treatment groups within a sin-
gle cell line or in tissue slice experiments was conducted
with parametric two-tailed, paired Student’s t-test using
Microsoft Excel 2003 software. The number of experi-
ments/number of animals executed is given as “n”. Joint
analysis of the three cell lines was conducted with the
non-parametric Wilcoxon rank sum test using SigmaPlot
11.0. In the joined analysis “n” represents the number of
cell lines. Values are presented as mean ± SEM, if not
otherwise noticed. P-values ≤ 0.05 (*; #) and ≤ 0.01 (**; ##)
were considered as statistically significant; p-values ≤ 0.001
(***; ###) as highly statistically significant.
Drug interaction analyses regarding synergistic or
additive effects were conducted as described previously
[18] using the Bliss independence (BI) model which is
based on the non-interaction theory [35, 36].
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Results
Short- and long-term survival of tumor cells
First, we recorded the short-time survival of human MB
cells after treatment with single modulators for 6 days
using the trypan blue exclusion assay. The rise of vital
untreated cells after 6 days compared to initially seeded
cells (D283-Med, 16-fold; MEB-Med8a, 41-fold; DAOY,
83-fold) reflects the different growth rates of the three
MB cell lines (Fig. 1). Although, short-time cytotoxic ef-
fects of the tested drugs may reduce the tumor bulk,
some (tumor stem) cells might not be targeted and lead
to quick tumor regrowth. Otherwise, cells might grow
well in short-term assays but lose their colony-forming
ability after a few cell divisions due to the accumulation
of DNA damages. Therefore, surviving cells were seeded
for clonogenic assays to examine the long-term repro-
ductive survival 10–14 days later (Fig. 2). The plating
efficiencies (PE) of untreated cell lines were very similar,
between 0.49 ± 0.05 (MEB-Med8a) and 0.56 ± 0.1 (DAOY)
(data not shown). From single drug clonogenic assays an
inhibitory concentration by which 90 % of clonogenic cells
were killed (IC 90) was calculated for each drug (listed in
Table 1). If not otherwise noted, these concentrations were
used for combination experiments presented individually
in Fig. 3 and for joined analysis of all three MB cell
lines in Fig. 4. Detailed statistical analysis of overall
clonogenic survival is summarized in Table 2.
Irradiation (IR)
After IR at 2 Gy, surviving fractions (SF) of clonogenic
cells were reduced to 0.17 ± 0.02 (D283-Med, n = 5),
0.34 ± 0.02 (MEB-Med8a, n = 5), and 0.61 ± 0.04 (DAOY,
n = 5) (Fig. 3). After IR at 8 Gy, SF was further reduced
to 1.63 E-03 ± 7.92 E-04 (D283-Med), 6.76 E-04 ± 8.94
E-05 (MEB-Med8a), and 1.82 E -02 ± 9.45 E-03 (DAOY)
(data not shown). The mean SF of all cell lines was
0.37 ± 0.13 at 2 Gy and 0.007 ± 0.006 at 8 Gy.
5-Aza-2′-deoxycytidine (5-aza-dC)
After 6 days of 5-aza-dC treatment, we observed a dose-
dependent and cell line-specific decline of short-time
survival (Fig. 1a) and long-term clonogenic survival
(Fig. 2a) in all three cell lines. Shortening of treatment
time to 3 days diminished the inhibitory effect (data not
shown). The slowly proliferating D283-Med cells (doub-
ling time DT = 40 h) exhibited the strongest sensitivity
(IC 90 = 0.05 μM), whereas the fast growing DAOY cells
(DT = 18 h) were most resistant to 5-aza-dC (IC 90 =
0.5 μM). Combination of 5-aza-dC with IR (2 Gy), led to
radiosynergistic effects in all cell lines and reduced the
Fig. 1 Relative number of vital MB cells after 6-day single drug treatment. The number of vital cells was examined by trypan blue exclusion assay
in three MB cell lines after 6-day treatment with: a) 5-aza-dC, b) VPA, c) SAHA, d) ATRA, e) ABC, f) RES. Five distinct drug concentrations were
applied and values are normalized to the initial-seeded cell number (dashed line). For each cell line one experiment was performed
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overall clonogenic survival by 15-fold (D283-Med, n = 5),
8-fold (MEB-Med8a, n = 5), and 34-fold (DAOY, n = 5)
compared to 5-aza-dC alone (Fig. 3).
Joint analysis of all three cell lines revealed a 13-fold
reduction of overall clonogenic survival by 5-aza-dC
alone (SF = 0.088 ± 0.02; p ≤ 0.001) and a 50-fold reduc-
tion by 5-aza-dC and 2 Gy (SF = 0.022 ± 0.01; p ≤ 0.001)
versus untreated control (Fig. 4).
Valproic acid (VPA)
Relatively high doses of VPA (>1 mM) were required to
reduce the short- and long-time survival in all MB cell
lines (Figs. 1b and 2b). Combination of 5-aza-dC and
VPA showed additive effects of VPA in D283-Med,
synergism in MEB-Med8a, but no further reduction in
DAOY on overall clonogenic survival compared to 5-
aza-dC alone. VPA acted radiosynergistically in D283-
Med and MEB-Med8a and radioadditively in DAOY
cells. Addition of VPA to 5-aza-dC and IR (2 Gy) led
to synergistic effects in MEB-Med8a only, reducing the
overall clonogenic survival further by 7-fold (Fig. 3a;
significances in Table 2).
Joint analysis of all MB cell lines (n = 3) revealed that
VPA alone induced a 3.7-fold decrease (SF = 0.27 ± 0.13;
p ≤ 0.001) and combined with 2 Gy and 5-aza-dC, a 104-
fold decrease (SF = 0.01 ± 0.007; p ≤ 0.001) of overall clo-
nogenic survival compared to untreated control (Fig. 4a;
significances Table 2).
Suberanilohydroxamic acid (SAHA)
The maximal tolerated SAHA plasma concentration in
humans of 2 μM [37] reduced the relative number of
vital cells only by 46–77 % compared to untreated cells
(Fig. 1c). In clonogenic assays, the IC 90 was reached
only in D283-Med cells. In MEB-Med8a and DAOY cells
SAHA (2 μM) resulted in a SF of 0.29 and 0.18 (Fig. 2c).
The combination of SAHA and 5-aza-dC revealed syn-
ergistic effects in D238-Med and additive effects in
MEB-Med8a and DAOY on overall clonogenic survival.
Combined with IR, SAHA showed radiosynergistic ef-
fects in D283-Med and DAOY and radioadditive effects
in MEB-Med8a. In 5-aza-dC/IR-treated cells, SAHA
induced additive effects in D283-Med cells and syner-
gistic effects in MEB-Med8a and DAOY cells. Thereby,
it further reduced the overall clonogenic survival of
Fig. 2 Clonogenic survival of MB cells after 6-day single drug treatment. Reproductive long-term survival was determined by clonogenic assays in
three MB cell lines after 6-day treatment with: a) 5-aza-dC, b) VPA, c) SAHA, d) ATRA, e) ABC, f) RES. Five distinct drug concentrations were applied
and values are normalized to untreated control. The experiment was performed once in sextuplicates. Data are presented as mean ± SEM. IC 90
values for combination experiments were calculated using Excel software and are shown in Table 1
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Fig. 3 Individual presentation of overall clonogenic survival in D283-Med, MEB-Med8a and DAOY after combined treatment with 5-aza-dC, IR with
2 Gy, and a) VPA, b) SAHA, c) ATRA, d) ABC, e) RES. Cells were treated with 5-aza-dC and a second drug (concentrations are shown in Table 1)
for 3 days pre- and 3 days post-IR (2 Gy). Clonogenic survival was examined 10–14 days later. Results after 8 Gy irradiation were similar (Table 2).
Data were normalized to the untreated, nonirradiated control (=1) and relative values presented as mean ± SEM from sextuplicates. Statistical
significances of treatment groups vs. control (0 or 2 Gy) are indicated by asterisks (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) and for combination
of all treatments (white bar) vs. 5-aza-dC + control by hash (#, respectively). Additional information about significant synergism/additivity and
intergroup significances is given in Table 2
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Fig. 4 (See legend on next page.)
Patties et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:94 Page 8 of 19
5-aza-dC/2 Gy-treated MB cells by 84-fold (D283-Med),
14,000-fold (MEB-Med8a), and 15-fold (DAOY) (Fig. 3b;
significances in Table 2).
Joint analysis of the three MB cell lines revealed a SF
of 0.036 ± 0.034 (p ≤ 0.001; n = 3) in SAHA treated cells.
Combination of SAHA with 2 Gy and 5-aza-dC reduced
the overall clonogenic survival 2,100-fold compared to
untreated control (SF = 4.75 E-04 ± 3.47 E-04; p ≤ 0.001;
n = 3) (Fig. 4b; significances in Table 2).
Abacavir (ABC)
The ABC treatment diminished the relative number of
vital cells (Fig. 1d) and the overall clonogenic survival
(Fig. 2d) in all cell lines with strongest effects on D283
cells. In clonogenic assays, the combination of ABC with
5-aza-dC revealed additive effects in D283-Med and
DAOY and synergistic effects in MEB-Med8a. Combined
with IR, ABC showed radiosynergistic effects in D283-
Med and DAOY and radioadditive effects in MEB-Med8a.
In the multimodal treatment with 5-aza-dC and IR, ABC
acted additively in all MB cell lines and further reduced
the overall clonogenic survival of 5-aza-dC/2 Gy-treated
cells by 7-fold (D283-Med), 540-fold (MEB-Med8a), and
90-fold (DAOY) (Fig. 3c; significances Table 2).
Joint analysis of all three MB cell lines revealed a
37-fold reduction of overall clonogenic survival by ABC
(SF = 0.027 ± 0.025; p ≤ 0.001, n = 3). After combination
of ABC with 2 Gy and 5-aza-dC, the overall clonogenic
survival was diminished 1,470-fold compared to un-
treated control (SF = 6.80 E-04 ± 5.95 E-04; p ≤ 0.001;
n = 3) (Fig. 4c; significances Table 2).
All-trans retinoic acid (ATRA)
ATRA induced differential responses. It reduced dose-
dependently the relative vital cell number and surviving
fraction (IC 90 = 1.5 μM) in D283-Med cells, whereas
in DAOY cells only a moderate response (estimated IC
90 = 10 μM), and in MEB-Med8a cells at concentrations
of up to 5 μM no response was induced (Figs. 1e and 2e).
Combined with 5-aza-dC, ATRA synergized in D283-
Med cells (49-fold reduction vs. 5-aza-dC) and showed
slight additive effects in DAOY (2.8-fold reduction vs.
5-aza-dC) and MEB-Med8a cells (1.3-fold reduction vs.
5-aza-dC). Also in combination with IR, ATRA induced
radiosynergistic effects in D283-Med and radioadditive
effects in MEB-Med8a and DAOY. In the multimodal
setting of ATRA with 5-aza-dC and IR, synergistic
effects were found in D283-Med and additive effects
in DAOY but not in MEB-Med8a cells. Compared to
5-aza-dC/2 Gy-treated cells the overall clonogenic sur-
vival was reduced by 44-fold and 2.8-fold, respectively
(Fig. 3d; significances Table 2).
Joint analysis of the MB cell lines revealed a 3.5-fold
decrease of overall clonogenic survival (SF = 0.28 ± 0.15;
p ≤ 0.001; n = 3) by ATRA alone. The combination of
ATRA with 2 Gy and 5-aza-dC showed a 54-fold reduction
compared to untreated control cells (SF = 0.019 ± 0.013;
p ≤ 0.001; n = 3) (Fig. 4d; significances Table 2).
Resveratrol (RES)
RES concentrations between 0.1–10 μM diminished the
relative number of vital cells and clonogenic survival
in D283-Med and MEB-Med8a cells, but only slightly
affected DAOY cells (Figs. 1f and 2f). Thus, for combi-
nation experiments, DAOY cells were treated with 40 μM
RES (IC 94), which is the maximum achievable plasma
concentration in animal experiments [26]. Combined with
5-aza-dC, RES reduced the overall clonogenic survival of
5-aza-dC-treated cells synergistically in D283-Med (110-
fold) and DAOY cells (14,000-fold), and additively in
MEB-Med8a cells (70-fold). Also in combination with IR,
RES showed radiosynergistic effects in D283-Med and
DAOY and radioadditive effects in MEB-Med8a cells.
The multimodal setting, combining RES with 5-aza-dC
and IR, revealed synergistic action of RES in all cell
lines. Thereby, it further reduced the SF of 5-aza-dC/2 Gy-
treated cells by 110-fold (D283-Med), 170-fold (MEB-
Med8a), and 5,000-fold (DAOY) (Fig. 3e; significances
Table 2).
Joint analyses of all three cell lines showed a 100-fold
reduction of overall clonogenic survival by RES alone
(SF = 0.01 ± 0.004; p ≤ 0.001). Combined with 2 Gy and
5-aza-dC, the overall clonogenic survival was reduced
6,350-fold compared to untreated cells (SF = 1.59 E-04 ±
1.32 E-04; p ≤ 0.001; n = 3) (Fig. 4e; significances Table 2).
Mechanistic studies of IR, 5-aza-dC, RES, and ABC in
tumor cells
The combination of IR and 5-aza-dC with RES or ABC
reduced the clonogenic survival of human MB cells most
efficiently compared to any other single or combined
drug treatment tested. To reveal the mechanism of
action we analyzed apoptosis, autophagy, cell cycle dis-
tribution, and DNA double-strand break repair after
(See figure on previous page.)
Fig. 4 Joint analysis of clonogenic survival in all three cell lines after combined treatment with 5-aza-dC, IR, and a) VPA, b) SAHA, c) ATRA, d) ABC,
e) RES . Relative data (untreated, nonirradiated control = 1) are presented as mean ± SEM, n = 3. Statistical significance is presented vs. control (0, 2
or 8 Gy, black bars) by asterisks (*, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001) and for multimodal combination (white bar) vs. 5-aza-dC + control (dark grey
bar) by hash (#, respectively) to clarify (1) the effects compared to irradiation alone and (2) the enhancement of the previously described effect of
5-aza-dC/IR [4]. Additional information about significant synergism/additivity is given in Table 2. Drug concentrations are shown in Table 1
Patties et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:94 Page 9 of 19
Table 2 Statistics - Clonogenic survival after combinatorial treatment
P-values were calculated by two-tailed, paired Student’s t-test in the single cell lines or by non-parametric Wilcoxon rank-sum test in the joint analysis of all cell
lines. The x-fold reductions of overall clonogenic survival compared to the indicated reference group are listed. Combinatorial effects conducted with the Bliss
independent model are indicated as A = additive or S = synergistic
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these most promising treatments using the cell line spe-
cific IC 90 of of 5-aza-dC, RES, or ABC (see Table 1)
and IR at 2 Gy.
Vital cell count, Apoptosis, and Autophagy
The joint analysis of all three MB cell lines revealed a
significant reduction of vital cell count 18 h after IR
(2 Gy) or treatment with 5-aza-dC, RES, or ABC by 25, 19,
37, or 23 %, respectively (n = 3, p ≤ 0.05. Fig. 5a). Responses
were similar in all three cell lines, except for DAOY cells
being the least sensitive for ABC and IR treatments.
Treatments led also to a significant increase of apop-
totic cells in caspase 3/7 induction assays (Fig. 5b) and
sub-G1 phase quantification (Fig. 6b) in joint analyses
(n = 3, p ≤ 0.05 to p ≤ 0.01). The strongest effects on cas-
pase 3/7 induction (18 h) and on sub-G1 apoptotic cell
fraction (24/72 h) were observed after RES treatment
and IR resulting in a significant 2.5-fold and 1.8-fold
Fig. 5 Vital cell count (a), Apoptosis (b), and Autophagy (c). Vital cell count was determined by trypan blue exclusion assay, apoptosis by FAM-FLICA™
in vitro Caspase 3/7 Detection Kit, and autophagy by Cyto-ID® Autophagy Detection Kit, 18 h after treatment with the single drugs (5-aza-dC, RES, ABC;
concentrations see Table 1) or irradiation with 2 Gy. Data were normalized to the untreated control group and presented as mean ± SEM,
n = 3. Statistical significances are presented vs. control by asterisks (*, p ≤ 0.05; **, p ≤ 0.01). The joint analysis included the relative data of
the three MB cell lines
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Fig. 6 Cell cycle distribution. 24 h and 72 h after treatment with single drugs (5-aza-dC, RES, ABC; concentrations see Table 1) or irradiation with
2 Gy, cells were fixed and stained with propidium iodide (PI). The fluorescence intensity of the PI-positive DNA correlates with the cell cycle phase
distribution and was measured by flow cytometry. a Histograms of the cell cycle distribution in untreated control cells. The different cell cycle
phases corresponding to the PI fluorescence intensity are indicated. b Relative fraction of cells distributed in sub-G1, G0/G1, S, or G2/M cell cycle
phase, grey bars: 24 h, black bars: 72 h after drug administration or IR. Values are normalized to control (=0) and presented as mean ± SEM, n = 3.
Statistical significances are presented vs. control by asterisks (*, p ≤ 0.05; **, p ≤ 0.01; ***, p≤ 0.001). The joint analysis included the relative data of
the three MB cell lines
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enhancement of caspase 3/7, respectively. This was
followed by a 5-fold and 9-fold increase of sub-G1 cells
72 h after RES treatment and IR. Single cell line analysis
revealed that MEB-Med 8a cells were most resistant
showing no significant induction of caspase 3/7, although
a significant enrichment of sub-G1 cells 72 h after RES
could be observed.
Autolysosome staining to assess autophagy induction
showed significant enhancements only after ABC or IR
treatment compared to control cells (joint analysis,
n = 3, p ≤ 0.05, Fig. 5c). Most pronounced effects were
detected in MEB-Med 8a cells (29-fold after IR, p ≤ 0.05).
Cell cycle distribution
Joint analyses of the three MB cell lines revealed a sig-
nificant increase of sub-G1 apoptotic cell population in
all treatment groups after 72 h (n = 3, p ≤ 0.05 to ≤ 0.01).
This effect was most pronounced after IR (2 Gy) and
RES treatment (Fig. 6b). 5-Aza-dC (72 h) and RES (24 h)
additionally induced a significant enriched S phase frac-
tion with a concomitant drop in G2/M cell fraction.
Similarly, 24 h after treatment with ABC, a significant
enrichment of S phase cells could be observed, though
without an impact on the G1 or G2/M cell fraction.
Only IR caused a significant G2/M arrest.
Within the cell lines, D283-Med cells showed the
strongest response, all single drugs induced a G1 arrest
accompanied by a decrease of G2/M cell fraction 72 h
after treatment.
DNA double-strand breaks
The IR-induced G2/M arrest goes along with significant
enhancement of gH2AX DNA repair protein expression
1 h after IR (2 Gy) in all three MB cells (Fig. 7). The num-
ber of gH2AX foci felt below control level after 24 h indi-
cating complete repair of IR-induced DSBs in surviving
cells. Also RES and ABC are able to induce gH2AX foci
at least in two of the three cell lines, whereas 5-aza-dC
induced the formation of gH2AX foci only in D283-
Med cells.
Neurotoxic studies in neural progenitor cells
Nestin-positive neural progenitors were analyzed by life-
imaging microscopy of cultured murine hippocampal
Fig. 7 Detection of DNA double-strand breaks (DSB). The DSB repair protein gH2AX was quantified by immune fluorescence microscopy after 1 h
and 24 h treatment with the single drugs (5-aza-dC, RES, ABC; concentrations see Table 1) or 1 h and 24 h after irradiation with 2 Gy. a Representative
images of gH2AX (red) and DAPI (blue) staining in DAOY cells; scale bar = 12 μm. b Treatment-induced gH2AX-foci relative to control cells in
the single MB cell lines. At least 50 nuclei were counted with a maximum of 30 foci per cell. Experiment was performed once and data are
presented as mean ± SEM. Statistical significances are presented vs. control by asterisks (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001)
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slices from transgenic nestin-CFPnuc C57BL/J6 mice to
examine potential neurotoxic effects of the most promising
multimodal approach (5-aza-dC + IR and RES or ABC)
(Fig. 8). To detect short- and long-term effects, analysis
were conducted at day 7, 14, 21 and 28 after treatment
start. Administration of 5-aza-dC and IR combined with
RES or ABC did not reduce the nestin-positive neural
progenitor cell pool compared to untreated control.
Discussion
Despite of surgery, irradiation, and chemotherapy, some
remaining therapy-resistant tumor cells may lead to tumor
relapse. Here, we follow the hypothesis that tumor control
might be enhanced by a multimodal treatment approach,
exploiting some of the hallmarks of cancer (detailed in
[38]). Based on the positive results of our previous studies
investigating the effects of IR and 5-aza-dC [4], and of
5-aza-dC with additional modulators [18], we investi-
gated here for the first time the effect of a triple com-
bination: IR, 5-aza-dC and one additional epigenetic
modifier (SAHA, VPA) or differentiation-inducer (RES,
ABC and ATRA).
To assess the impact of each treatment component, we
examined single and combinatorial effects on short-term
survival and long-term reproductive survival in three hu-
man MB cell lines. We emphasize that all drug concentra-
tions used here, except of VPA and ABC, are within the
range achievable in human or animal plasma [23–28].
Irradiation
In accordance to our previous results [18], the MB cell
line with the slowest growth rate (D283-Med) was found
to be most sensitive to IR, whereas the one with the
fastest growth rate (DAOY) was the least sensitive con-
cerning the reduction of short-term vitality, enrichment
of apoptotic sub-G1 cells, and also of long-term repro-
ductive survival. Although a higher amount of untreated
D283-Med cells is located in the radiosensitive G2/M
cell cycle phase compared to DAOY cells which exhib-
ited a higher amount of radioresistant G1/G0 cells, more
DSBs were induced in the DAOY then in D283-Med
cells. We hypothesize that the p53-wild-type D283-Med
cells may prefer non-homologous end-joining (NHEJ) as
the main DNA repair pathway which is usually executed
within minutes after IR (reviewed in [39]) and, therefore,
it is probably not seen 1 h after IR. As NHEJ is more
error-prone than the DSB repair by homologue recombin-
ation (HR), this might explain the enhanced sub-G1 apop-
totic cell fraction observed in D238-Med. Nevertheless,
DSB repair was completed 24 h after IR in the surviving
cells of both cell lines. Our results show, that the induction
of gH2AX foci by IR is accompanied with an enhanced
G2/M arrest in p53-mutant DAOYcells. This is in line with
findings in other tumor cells [40]. Additionally, we ob-
served that IR induces autophagy in human MB cells. It is
already known that IR may induce autophagy as a rescue
mechanism resulting in radioresistance but also as cyto-
toxic process resulting in cell death (reviewed in [41, 42]).
However, we revealed that autophagy did not account
for the long-term radiosensitivity of clonogenic MB
cells indicating that other mechanisms such as DSB re-
pair efficiency, suggested by the results above, may play
a role here.
The multimodal treatments with 8 Gy IR generally
support the findings after IR with 2 Gy (Table 2). Fewer
significances found for combinatorial treatments are
Fig. 8 Life imaging analysis of neural progenitor cell number in murine hippocampal tissue slice cultures. The number of nestin-positive cells is
shown at day 0, 7, 14, 21, and 28 after IR (8 Gy) or combinatorial treatment with 5-aza-dC, IR and RES or ABC. Ethanol control was included as RES
was dissolved in ethanol. Data are normalized to the untreated control group (=1). Results are presented as mean ± SEM; *, p≤ 0.05; n = 6 com-
pared to untreated control
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possibly due to the much lower overall surviving fraction
after 8 Gy IR compared with 2 Gy IR.
5-Aza-2′-deoxycytidine (5-aza-dC)
The 5-aza-dC-induced enhancement of mortality, inhib-
ition of proliferation, and reduction of clonogenic survival
in all three MB cell lines confirm our previous data [4].
Both, its ability to form DNA enzyme adducts (5-aza-dC/
DNMT) inhibiting cell cycle progression and also leading
to DSB as well as its function as de novo methyltransferase
inhibitor (DNMTi) [43] are thought to contribute to these
anti-cancer effects. The lack of 5-aza-dC-induced apop-
tosis and autophagy demonstrated here goes along with
the only weak induction of gH2AX foci, mainly seen in
D283-Med cells. Therefore, we assume that the 5-aza-dC-
induced reduction of the short-term and long-term sur-
vival in MB cells might be rather caused by its inhibition
of proliferation and/or epigenetic properties [4, 44, 45].
We demonstrated a radiosynergistic reduction of over-
all clonogenic survival after combining 5-aza-dC with
IR. By modulation of the former treatment schedule (5-
aza-dC only prior to IR) to 5-aza-dC treatment prior
and after IR, we could improve the previously found
radioadditive effect of 5-aza-dC [4]. This 5-aza-dC-in-
duced enhancement of radiosensitivity has also been
described in other tumor entities [46–49]. It has been
suggested by others that the induction of a G2/M arrest
by 5-aza-dC treatment prior to IR may account at least
partly for its radiosensitizing effect [48]. This could not
be confirmed by our findings. Joint analysis of our MB
cell lines demonstrated a slightly prolonged DNA synthe-
sis cell cycle phase possibly resulting in the reduced G2/M
fraction, after 24 h 5-aza-dC treatment. Additional
mechanisms like the p53-dependent induction of sen-
escence demonstrated in hepatocellular carcinoma [50]
might play a role here and also could explain the in-
creased sensitivity of p53-wild-type D283-Med and
MEB-Med8a cells compared to p53-mutated DAOY
cells. Similarly, in experiments with colon cancer cells,
Karpf et al. revealed that 5-aza-dC is more effective to
mediate growth arrest and cytotoxicity in p53-wild-
type versus p53-mutated cells [51]. These observations
indicate that the treatment of MB patients with p53
wild-type tumors (the majority of patients) might re-
quire lower 5-aza-dC concentrations than the one with
p53-mutated tumors.
Valproic acid (VPA)
VPA, a histone deacetylase inhibitor (HDACi) [52] and
a replication-independent DNMTi [53] induced a mode-
rate decline in relative vital MB cell number and clo-
nogenic survival, which goes along with our previous
findings [18], and supports its anti-tumor effects reported
in other tumor models [54, 55].
VPA induces apoptosis and growth arrest in MB cells
by a p53-independent mechanism through alteration of
histone acetylation and thereby gene and protein expres-
sion [52]. Indeed, all three tested MB cell lines showed
largely similar sensitivities to VPA alone. The combin-
ation of VPA and 5-aza-dC showed differential effects
on MB cell overall clonogenic survival and the previ-
ously measured metabolic activity [18]. After treatment,
an enhanced metabolic activity but a reduced clonogenic
potential was found in MEB-Med8a cells. In DAOY
cells however, despite of reduced metabolic activity,
the clonogenicity was slightly enhanced. These results
emphasize the importance of long-term reproductive
survival assays to evaluate the clonogenic potential of
tumor stem cells after different treatment regimes.
The radiosynergistic effect of VPA on clonogenic survival,
demonstrated in two cell lines here, goes along with
findings in glioma cell lines and in a glioma xenograft
mouse model, where an inhibition of radiation-induced
DSB repair by VPA has been suggested [56]. Our results
underline the potential of VPA in combination with
radio- and chemotherapy, recently demonstrated in
retrospective studies of glioblastoma patients [57, 58].
Suberanilohydroxamic acid (SAHA)
The HDACi SAHA alone only slightly reduced the
clonogenic survival despite of its strong effect on the
metabolic activity published previously [18]. Interestingly,
addition of SAHA significantly diminished the 5-aza-dC-
induced reduction of overall clonogenic survival in all MB
cell lines. Strong additive effects of 5-aza-dC and SAHA
are described also by others in leukemic and ovarian can-
cer cell lines and are thought to be transmitted through
the induction of cell cycle arrest (G1/S by SAHA; G2/M
by 5-aza-dC) and apoptosis [59, 60].
The combination of SAHA with IR showed radiosy-
nergistic effects on overall clonogenic survival in all
tested MB cell lines, even slightly stronger than found
with VPA. Similarly, other groups observed a radiosensi-
tizing action of SAHA on osteosarcoma and atypical ter-
atoid rhabdoid tumor cells in vitro and in a rhabdoid
tumor mouse model in vivo [61, 62]. Regarding 5-aza-
dC-treated irradiated MB cells, SAHA induced synergistic
effects on overall clonogenic survival in all three tested
MB cell lines and in this combination seems to be more
effective than the HDACi VPA.
Abacavir (ABC)
ABC has been shown to down-regulate the telomerase
activity, which is overexpressed in the vast majority of
cancers including MB [63]. Sparing normal brain cells
due to their low or even not existing telomerase activity,
the inhibition of telomerase in brain tumor cells seems
to be a promising therapeutic strategy for MB. ABC
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alone decreased the overall clonogenic survival in all MB
cell lines. The ABC-induced reduction of vital cell count
goes along with its induction of apoptosis and auto-
phagy. Importantly, we found that ABC acts strongly ad-
ditive with 5-aza-dC on the reduction of the overall
clonogenic survival in all three MB cell lines. It seems
worthwhile to investigate this combination in animal
models to clarify if it could be an alternative therapy
option for infants (<4 years), who cannot obtain radio-
therapy due to unwanted adverse effects.
Our experiments revealed also radiosynergistic (DAOY,
D283-Med) and radioadditive (MEB-Med8a) effects of
ABC on the overall clonogenic survival. In accordance, it
has been shown that the inhibition of telomerase activity
can sensitize tumor cells to irradiation [64, 65], partly me-
diated by prolongation of DSB repair. In two-out-of-three
cell lines we found indeed a higher amount of gH2AX
foci after 24 h ABC treatment compared to control.
MEB-Med8a behaved differentially possibly due to a
high amount of initial (control) DSB. It has been sug-
gested that the upregulation of telomerase activity in
tumor cells may represent a protective mechanism
against DNA damage [65]. This hypothesis is supported
by Akiyama et al., who showed that the overexpression
of telomerase protects leukemia cells from DSB-triggered
apoptosis [66].
The ABC-induced significant reduction of overall
clonogenic survival in all 5-aza-dC/IR-treated MB cell
lines indicated a therapeutic potential of the triple
combination.
All-trans retinoic acid (ATRA)
ATRA, the prototype of differentiation therapy, induced
differential responses in the three MB cell lines. Similar
to our previous studies on metabolic activity [18], the
strongest effect on overall clonogenic survival was found
in the OTX2-expressing D283-Med cell line, supporting
recent findings of OTX2 as a medulloblastoma oncogene
and possible target for ATRA [67]. MEB-Med8a cells
seemed to be ATRA-resistant, whereas in DAOY cells a
moderate effect was seen. In accordance, an ATRA-
mediated induction of caspase 3 followed by inhibition of
proliferation and apoptosis was reported in D283-Med cells
and to a lesser extend in DAOY cells [68]. Also, enhance-
ment of OTX2 (orthodenticle homeobox 2) protein levels,
involved in ATRA-mediated tumor cell death, has been
shown in D283-Med but not in DAOY cells [67].
By combination of ATRA and 5-aza-dC as well as ATRA
and IR, we showed synergism in D283-Med (1.5 μM), a
moderate reduction of clonogenicity in DAOY and also
in the ATRA-resistant MEB-Med8a cell line, although
at relatively high doses (10 μM) only. We hypothesize
that this synergistic effect could be caused by 5-aza-dC-
induced demethylation of the CRABP-II gene as
suggested by Fu et al. [69]. Therefore, ATRA, if com-
bined with demethylating agents, might be an interest-
ing substance to treat MB tumor stem cells to bypass
their radio- and chemoresistance.
Resveratrol
The plant polyphenol RES exhibits tumor-preventive as
well as anticancer effects depending on concentration,
cell type, and microenvironment [21, 70–72]. Studies in
MB cells have shown the induction of cell cycle arrest,
apoptosis and neuronal differentiation by RES [73–75].
In accordance, we could show a RES-mediated prolonga-
tion of DNA synthesis cell cycle phase with an increase
of gH2AX foci formation. This is followed by the reduc-
tion of vital cell count partially due to the induction of
apoptosis. Our previous experiments revealed synergistic
effects with 5-aza-dC on the metabolic activity of human
MB cell lines [18]. Our recent data from clonogenic sur-
vival experiments confirm an anti-cancer effect of RES
combined with 5-aza-dC and/or IR in all three MB cell
lines. Although RES has been shown to prevent normal
cells from treatment-induced damage [18, 72, 76, 77],
used on its own, it seems to induce adverse effects [78].
It is of special interest that combinatorial treatments
with RES reduced the overall clonogenic survival most
strongly in the p53-mutated DAOY cell line. Numerous
clinical studies confirmed the unfavorable prognosis of
patients with p53-mutated MBs (about 10 % of all MB
patients); they all died in the first 5 years after diagnosis
[79–83]. Animal experiments are warranted to reveal if
RES might be an interesting adjuvant therapy option for
high-risk patients with p53-mutated tumors.
Neurotoxicity of 5-aza-dC, RES, and ABC
This is the first report showing data concerning the
neurotoxicity of a multimodal anti-tumor treatment ap-
proach with 5-aza-dC, IR, and RES or ABC using a mu-
rine hippocampal tissue slice model. Thereby, no toxic
effects on neural progenitor cells were observed. Park et
al. revealed adverse effects of RES alone on the murine
hippocampal neurogenesis and cognitive function in vivo
and in vitro [78]. However, in accordance to our obser-
vations, Denissova et al. [84] showed that RES en-
hances the survival of irradiated mouse embryonic
stem cells by accelerating and refining radiation-induced
DNA repair.
The nucleoside analogue ABC is known to have a high
potential risk of neuronal damage in primary cell cul-
tures of rat forbrain [85]. Nevertheless, in our murine ex
vivo hippocamal tissue slice model we could not detect
any significant neurotoxicity of ABC in combination
with 5-aza-dC and IR regarding nestin-positive neural
precursor cells.
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Conclusion
The differential results of short- and long-term survival
in these and also metabolic tests in previous studies [18]
underline the importance of clonogenic assays. Success-
ful antitumor therapy may benefit from personalized
medicine reflected here in the case of ATRA, working
best in selected OTX2 expressing samples. Nevertheless,
the triple combination of 5-aza-dC/IR and ABC or RES
turned out to work effectively in all three cell lines
warranting further in vivo investigations.
Long-term analysis of neural stem cell numbers in a
murine hippocampal slice culture model revealed no
neurotoxic potential for these drug combinations. Also
VPA and SAHA reduced the reproductive survival of
5-aza-dC/IR treatments further but to a lower extend.
The most powerful combinations of our in vitro exper-
iments warrant in vivo experiments in an orthotopic MB
mouse model. If successfully translated in vivo, especially
the combination experiments without IR might provide
adjuvant alternative therapy strategies in infants (<4 years).
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